Shopping Cart
Remove All
Your shopping cart is currently empty
Indeglitazar (PPM 204) is orally available pan-agonist of PPAR (PPAR subtypes alpha (α), delta (δ), and gamma (γ)).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $48 | In Stock | In Stock | |
| 10 mg | $64 | In Stock | In Stock | |
| 25 mg | $129 | In Stock | In Stock | |
| 50 mg | $197 | In Stock | In Stock | |
| 100 mg | $297 | In Stock | In Stock | |
| 200 mg | $455 | In Stock | In Stock |
| Description | Indeglitazar (PPM 204) is orally available pan-agonist of PPAR (PPAR subtypes alpha (α), delta (δ), and gamma (γ)). |
| In vitro | Measuring in part functional insulin sensitization capability of the cells, Indeglitazar shows an EC50 of 0.32 μM compared with Rosiglitazone, which shows an EC50 of 13 nM, in an assay of preadipocyte differentiation[1]. |
| In vivo | In Zucker rat model of diabetes, Indeglitazar (10 mg/kg; i.v.) significantly lowers the levels of glucose, HbA1C, triglycerides. In the ob/ob model of diabetes and insulin resistance, Indeglitazar significantly decreases glucose, insulin, triglycerides, and free fatty acid levels. The level of Adiponectin (day 21) is essentially unchanged, thus the observed reductions in glucose and HbA1C are achieved in an adiponectin-independent fashion[1]. |
| Synonyms | PPM 204 |
| Molecular Weight | 389.42 |
| Formula | C19H19NO6S |
| Cas No. | 835619-41-5 |
| Smiles | COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12 |
| Relative Density. | 1.34 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (231.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.